Cancer Therapeutics CRC signs agreement with global pharma heavyweight Pfizer

Cancer Therapeutics CRC (CTx) has signed a two-year research partnership and licensing deal with Pfizer. With this agreement, the global pharmaceutical gains the rights to two novel pre-clinical cancer programs that focus on proteins closely linked to the growth of solid and blood cancer. Exploring these programs could lead to new cancer treatments.

For these two programs, CTx received a signature payment of AUD$20M with the potential for up to AUD$648M for development and sales milestones, plus royalties on sales if program outcomes are commercialized.

“This deal, together with the three prior deals for CTX technology, has the potential to return a billion dollars to Australia. Funds that will help support the biomedical sector and that can be ploughed into new drug discovery programs”, said Brett Carter, CEO of CTx.

This partnership between the Melbourne-based CTx and NY-based Pfizer is the second significant preclinical licensing deal that CTx has completed with a major pharmaceutical company and adds significantly to the already impressive list of commercial achievements by CTx in recent years. The previous license with MSD (Merck in North America) was signed in January 2016.

BioMedVic congratulates its member CTx for reaching this agreement with Pfizer. BioMedVic’s Board is currently Chaired by Dr Warwick Tong, who until April 2018 was the CEO of CTx. Dr Tong is now CTx’s Advisor and Chair of its spin-out company CTx One. BioMedVic’s Board past Chair, Dr George Mortsyn, is also an Independent Director on the CTx Board.

More information can be found in the press release by Cancer Therapeutics CRC, and in the article published last Friday by the Australian Financial Review.

Growing health services research in Victoria

BioMedVic continues to build relations and work in partnership with the Victorian Government on key topics for the state and sector. With the Victorian Cancer Agency and the Office of Health and Medical Research, BioMedVic recently conducted a joint workshop to identify strategies to build capacity in health services research (HSR) in Victoria.

Continue reading

All Eyes on Victoria at AusBiotech 2016

We’ve been busy in the lead up to the AusBiotech 2016 International BioFest conference this month, ensuring our researchers from academia and industry receive the attention they deserve. BioMedVic assisted the Victorian Government with the state’s presence at the event which attracted an estimated 2,000 delegates.

BioMedVic organised and managed the roster of the Victorian industry and research participants at the Government’s BioIndustry Exhibition booth.

Continue reading

BioMedVic Members in the Spotlight at AusBiotech 2016

Members will be pleased to hear that – once again – Biomedical Research Victoria is assisting the Victorian Government with the state’s presence at the upcoming AusBiotech 2016 International BioFest conference.

The event is expected to attract over 2,000 delegates from around the world to Melbourne in October – and we have been busy ensuring Victorian researchers from academia and industry receive the attention they deserve.  Continue reading

CSL to support UROP stipends

BioMedVic is delighted to announce that for the first round of intake this year, long term sponsor, CSL, will provide 6 stipends, worth more than $50,000, to support the UROP placements for students in addition to the renewal of their principal funding of the UROP scheme.

Continue reading